These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. The role of sodium-glucose co-transporter 2 protein inhibitors in heart failure: more than an antidiabetic drug? Savarimuthu S; Harky A Expert Opin Pharmacother; 2022 Feb; 23(3):377-386. PubMed ID: 34713764 [TBL] [Abstract][Full Text] [Related]
27. The role of sodium-glucose co-transporter (SGLT)-2 inhibitors in heart failure management and implications for the kidneys. Lioudaki E; Joslin JR; Trachanatzi E; Androulakis E Rev Cardiovasc Med; 2022 Mar; 23(3):82. PubMed ID: 35345249 [TBL] [Abstract][Full Text] [Related]
28. Response to: Correspondence on "Sodium-glucose co-transporter 2 inhibitor therapy: mechanisms of action in heart failure" by Yalta Joshi SS; Singh T; Singh J; Newby DE Heart; 2021 Dec; 107(23):1922-1923. PubMed ID: 34656972 [No Abstract] [Full Text] [Related]
29. Sodium-glucose co-transporter-2 inhibitors and sacubitril/valsartan combination in patients with heart failure with reduced ejection fraction; does it deserve our attention? Patoulias D; Papadopoulos C; Doumas M Am Heart J; 2021 Jun; 236():104-105. PubMed ID: 33902820 [No Abstract] [Full Text] [Related]
30. Cardiometabolic phenotype of heart failure with preserved ejection fraction as a target of sodium-glucose co-transporter 2 inhibitors and glucagon-like peptide receptor agonists. Volpe M; Gallo G Cardiovasc Res; 2021 Jul; 117(9):1992-1994. PubMed ID: 33231613 [No Abstract] [Full Text] [Related]
32. Sodium-glucose co-transporter 2 inhibitors in heart failure: beyond glycaemic control. A position paper of the Heart Failure Association of the European Society of Cardiology. Seferović PM; Fragasso G; Petrie M; Mullens W; Ferrari R; Thum T; Bauersachs J; Anker SD; Ray R; Çavuşoğlu Y; Polovina M; Metra M; Ambrosio G; Prasad K; Seferović J; Jhund PS; Dattilo G; Čelutkiene J; Piepoli M; Moura B; Chioncel O; Ben Gal T; Heymans S; de Boer RA; Jaarsma T; Hill L; Lopatin Y; Lyon AR; Ponikowski P; Lainščak M; Jankowska E; Mueller C; Cosentino F; Lund L; Filippatos GS; Ruschitzka F; Coats AJS; Rosano GMC Eur J Heart Fail; 2020 Sep; 22(9):1495-1503. PubMed ID: 32618086 [TBL] [Abstract][Full Text] [Related]
33. Correspondence on "Sodium-glucose co-transporter 2 inhibitor therapy: mechanisms of action in heart failure" by Joshi Yalta K; Ozkan U; Yalta T Heart; 2021 Dec; 107(23):1922. PubMed ID: 34656974 [No Abstract] [Full Text] [Related]
34. Comment on Sodium-Glucose Co-Transporter 2 Inhibitors and Heart Failure. Cure E; Cumhur Cure M Am J Cardiol; 2020 May; 125(10):1602. PubMed ID: 32241553 [No Abstract] [Full Text] [Related]
35. Treatment of heart failure with sodium glucose co-transporter-2 inhibitors in people with type 2 diabetes mellitus: current evidence and future directions. Sharma A; Butler J; Zieroth S; Giannetti N; Verma S Diabet Med; 2019 Dec; 36(12):1550-1561. PubMed ID: 31536660 [TBL] [Abstract][Full Text] [Related]
36. SOLOIST-WHF and updated meta-analysis: sodium-glucose co-transporter 2 inhibitors should be initiated in patients hospitalized with worsening heart failure. Docherty KF; McMurray JJV Eur J Heart Fail; 2021 Jan; 23(1):27-30. PubMed ID: 33283384 [No Abstract] [Full Text] [Related]
37. Effects of sodium-glucose co-transporter 2 inhibition with empagliflozin on potassium handling in patients with acute heart failure. Beusekamp JC; Tromp J; Boorsma EM; Heerspink HJL; Damman K; Voors AA; van der Meer P Eur J Heart Fail; 2021 Jun; 23(6):1049-1052. PubMed ID: 33899306 [No Abstract] [Full Text] [Related]
38. A mechanistic rationale for the investigation of sodium-glucose co-transporter 2 inhibitors in heart failure with preserved ejection fraction. Letter regarding the article 'Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR-Preserved trial'. Pabel S; Hamdani N; Sossalla S Eur J Heart Fail; 2021 May; 23(5):841. PubMed ID: 33377246 [No Abstract] [Full Text] [Related]
39. [ANMCO Position paper: Sodium-glucose co-transporter 2 inhibitors for the prevention of heart failure in diabetic patients and for the treatment of heart failure patients with and without diabetes]. Gronda E; Napoli C; Iacoviello M; Urbinati S; Caldarola P; Mannucci E; Colivicchi F; Gabrielli D G Ital Cardiol (Rome); 2021 Aug; 22(8):675-687. PubMed ID: 34310573 [TBL] [Abstract][Full Text] [Related]
40. Treatment of Hypertension to Prevent and Treat Heart Failure in Diabetic Patients Should Include Sodium Glucose Co-Transporter 2 Inhibitors. Carbone S; Dixon DL; Abbate A JACC Heart Fail; 2018 Jan; 6(1):85. PubMed ID: 29284585 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]